

Yusuke Furukawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5864973/publications.pdf>

Version: 2024-02-01

170
papers

6,277
citations

76196

40
h-index

79541

73
g-index

181
all docs

181
docs citations

181
times ranked

6949
citing authors

#	ARTICLE	IF	CITATIONS
1	Fast in-vitro screening of FLT3-ITD inhibitors using silkworm-baculovirus protein expression system. PLoS ONE, 2022, 17, e0261699.	1.1	0
2	AMP-activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCR-ABL protein in CML cells. Cancer Science, 2021, 112, 194-204.	1.7	8
3	Bone marrow stromal cell-mediated degradation of CD20 leads to primary rituximab resistance in mantle cell lymphoma. Leukemia, 2021, 35, 1506-1510.	3.3	3
4	Identification of characteristic proteins at late-stage erythroid differentiation in vitro. Human Cell, 2021, 34, 745-749.	1.2	2
5	mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3-and Blimp-1-mediated BCL-2 up-regulation. Haematologica, 2021, 106, 3008-3013.	1.7	6
6	Autophagic degradation of NOXA underlies stromal cell-mediated resistance to proteasome inhibitors in mantle cell lymphoma. Leukemia Research, 2021, 111, 106672.	0.4	1
7	K15 promoter-driven enforced expression of NKIRAS exhibits tumor suppressive activity against the development of DMBA/TPA-induced skin tumors. Scientific Reports, 2021, 11, 20658.	1.6	1
8	Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7. Leukemia, 2020, 34, 180-195.	3.3	47
9	Kinetics of cytokine receptor internalization under steady-state conditions affects growth of neighboring blood cells. Haematologica, 2020, 105, e325-e327.	1.7	1
10	Serum Endocrine Fibroblast Growth Factors as Potential Biomarkers for Chronic Kidney Disease and Various Metabolic Dysfunctions in Aged Patients. Internal Medicine, 2020, 59, 345-355.	0.3	14
11	Molecular basis of clonal evolution in multiple myeloma. International Journal of Hematology, 2020, 111, 496-511.	0.7	42
12	Splicing- and demethylase-independent functions of LSD1 in zebrafish primitive hematopoiesis. Scientific Reports, 2020, 10, 8521.	1.6	6
13	Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy. Leukemia, 2020, 34, 3088-3090.	3.3	7
14	Eradication of Central Nervous System Leukemia of T-Cell Origin with a Brain-Permeable LSD1 Inhibitor. Clinical Cancer Research, 2019, 25, 1601-1611.	3.2	17
15	Conversion of human fibroblasts into multipotent cells by cell-penetrating peptides. Biochemical and Biophysical Research Communications, 2019, 518, 134-140.	1.0	4
16	Lysine-specific demethylase 1 accelerates oncogenesis in p53 heterozygous mice via transcriptional repression of the residual Trp53 allele. Leukemia Research, 2019, 82, 29-32.	0.4	0
17	Myeloma Cells Are Activated in Bone Marrow Microenvironment by the CD180/MD-1 Complex, Which Senses Lipopolysaccharide. Cancer Research, 2018, 78, 1766-1778.	0.4	23
18	Cell adhesion-induced phosphorylation and inactivation of EZH2 confer drug resistance to acute myeloid leukemia cells. International Journal of Hematology, 2018, 107, 383-385.	0.7	0

#	ARTICLE	IF	CITATIONS
19	Lysine-specific demethylase 1 inhibitors prevent teratoma development from human induced pluripotent stem cells. <i>Oncotarget</i> , 2018, 9, 6450-6462.	0.8	14
20	Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines. <i>PLoS ONE</i> , 2017, 12, e0188680.	1.1	32
21	Multiple Myeloma: bench to bedside.. <i>Denki Eido</i> , 2017, 61, 93-96.	0.0	0
22	Histone deacetylases as novel therapeutic targets for refractory and relapsed multiple myeloma. <i>Annals of Oncology</i> , 2016, 27, vii31.	0.6	0
23	Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma. <i>International Journal of Hematology</i> , 2016, 104, 281-292.	0.7	44
24	Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 94-105.	1.9	23
25	Overexpression of the shortest isoform of histone demethylase LSD1 primes hematopoietic stem/progenitor cells for malignant transformation. <i>Experimental Hematology</i> , 2015, 43, S63.	0.2	0
26	Overexpression of the shortest isoform of histone demethylase LSD1 primes hematopoietic stem cells for malignant transformation. <i>Blood</i> , 2015, 125, 3731-3746.	0.6	47
27	Arf tumor suppressor disrupts the oncogenic positive feedback loop including c-Myc and DDX5. <i>Oncogene</i> , 2015, 34, 314-322.	2.6	28
28	Molecular pathogenesis of multiple myeloma. <i>International Journal of Clinical Oncology</i> , 2015, 20, 413-422.	1.0	52
29	Soluble Î±Klotho as a candidate for the biomarker of aging. <i>Biochemical and Biophysical Research Communications</i> , 2015, 467, 1019-1025.	1.0	36
30	Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma. <i>Journal of Clinical Investigation</i> , 2015, 125, 4375-4390.	3.9	85
31	Romidepsin Overcomes Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma Cells. <i>Acta Haematologica</i> , 2014, 132, 1-4.	0.7	7
32	Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2014, 28, 1216-1226.	3.3	55
33	Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells. <i>International Journal of Hematology</i> , 2014, 99, 726-736.	0.7	12
34	Purine Analog-Like Properties of Bendamustine Underlie Rapid Activation of DNA Damage Response and Synergistic Effects with Pyrimidine Analogues in Lymphoid Malignancies. <i>PLoS ONE</i> , 2014, 9, e90675.	1.1	25
35	The Novel Orally Active Proteasome Inhibitor K-7174 Exerts Anti-myeloma Activity in Vitro and in Vivo by Down-regulating the Expression of Class I Histone Deacetylases. <i>Journal of Biological Chemistry</i> , 2013, 288, 25593-25602.	1.6	23
36	Alkylating agents induce histone H3K18 hyperacetylation and potentiate HDAC inhibitor-mediated global histone acetylation and cytotoxicity in mantle cell lymphoma. <i>Blood Cancer Journal</i> , 2013, 3, e169-e169.	2.8	12

#	ARTICLE	IF	CITATIONS
37	BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia. <i>Oncogene</i> , 2013, 32, 1670-1681.	2.6	7
38	Homopiperazine Derivatives as a Novel Class of Proteasome Inhibitors with a Unique Mode of Proteasome Binding. <i>PLoS ONE</i> , 2013, 8, e60649.	1.1	14
39	Promoter methylation confers kidney-specific expression of the <i>Klotho</i> gene. <i>FASEB Journal</i> , 2012, 26, 4264-4274.	0.2	75
40	Histone deacetylase 1 enhances microRNA processing via deacetylation of DGCR8. <i>EMBO Reports</i> , 2012, 13, 142-149.	2.0	71
41	Reduced Histone H3K9 Acetylation of Clock Genes and Abnormal Glucose Metabolism in <i>ob/ob</i> Mice. <i>Chronobiology International</i> , 2012, 29, 982-993.	0.9	15
42	Latexin regulates the abundance of multiple cellular proteins in hematopoietic stem cells. <i>Journal of Cellular Physiology</i> , 2012, 227, 1138-1147.	2.0	20
43	BCR-ABL Regulates Death Receptor Expression for TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Philadelphia Chromosome-Positive Leukemia. <i>Blood</i> , 2011, 118, 2740-2740.	0.6	0
44	Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19). <i>Blood</i> , 2010, 116, 962-970.	0.6	35
45	Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. <i>Blood</i> , 2010, 116, 406-417.	0.6	121
46	HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. <i>Leukemia</i> , 2010, 24, 1760-1768.	3.3	86
47	MSK1 activation in acute myeloid leukemia cells with FLT3 mutations. <i>Leukemia</i> , 2010, 24, 1087-1090.	3.3	16
48	Inactivation of the Retinoblastoma Protein by Mutant B-Raf in Malignant Melanoma. <i>Nature Precedings</i> , 2010, , .	0.1	0
49	Up-regulation of Survivin by the E2A-HLF Chimera Is Indispensable for the Survival of t(17;19)-positive Leukemia Cells. <i>Journal of Biological Chemistry</i> , 2010, 285, 1850-1860.	1.6	15
50	Vinculin Is Indispensable for Repopulation by Hematopoietic Stem Cells, Independent of Integrin Function. <i>Journal of Biological Chemistry</i> , 2010, 285, 31763-31773.	1.6	23
51	Expression Levels of Histone Deacetylases Determine the Cell Fate of Hematopoietic Progenitors. <i>Journal of Biological Chemistry</i> , 2009, 284, 30673-30683.	1.6	68
52	Transactivation of RON receptor tyrosine kinase by interaction with PDGF receptor β^2 during steady-state growth of human mesangial cells. <i>Kidney International</i> , 2009, 75, 1173-1183.	2.6	21
53	Schedule-dependent synergism and antagonism between pemetrexed and docetaxel in human lung cancer cell lines in vitro. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 1129-1137.	1.1	4
54	Vasoactive intestinal peptide and inflammatory cytokines enhance vascular endothelial growth factor production from epidermal keratinocytes. <i>British Journal of Dermatology</i> , 2009, 161, 1232-1238.	1.4	21

#	ARTICLE	IF	CITATIONS
55	Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. <i>Oncogene</i> , 2009, 28, 231-242.	2.6	171
56	Ablation of Neutral Cholesterol Ester Hydrolase 1 Accelerates Atherosclerosis. <i>Cell Metabolism</i> , 2009, 10, 219-228.	7.2	93
57	A novel missense mutation of ABCA1 in transmembrane α -helix in a Japanese patient with Tangier disease. <i>Atherosclerosis</i> , 2009, 206, 216-222.	0.4	8
58	Ectopic Expression and Role of RCAN1 in Myeloid Leukemia Cells.. <i>Blood</i> , 2009, 114, 1274-1274.	0.6	1
59	The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro. <i>Anticancer Research</i> , 2009, 29, 4589-96.	0.5	12
60	The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations. <i>Oncogene</i> , 2008, 27, 3102-3110.	2.6	27
61	Transcriptional Modulation Using HDACi Depsipeptide Promotes Immune Cell-Mediated Tumor Destruction of Murine B16 Melanoma. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1506-1516.	0.3	84
62	Activation of Focal Adhesion Kinase in Detached Human Epidermal Cancer Cells and Their Long-term Survival Might be Associated with Cell Surface Expression of Laminin-5. <i>Acta Dermato-Venereologica</i> , 2008, 88, 100-107.	0.6	4
63	CD43, but not P-Selectin Glycoprotein Ligand-1, Functions as an E-Selectin Counter-Receptor in Human Pre-B α Cell Leukemia NALL-1. <i>Cancer Research</i> , 2008, 68, 790-799.	0.4	30
64	Cholesterol Reduction and Atherosclerosis Inhibition by Bezafibrate in Low-Density Lipoprotein Receptor Knockout Mice. <i>Hypertension Research</i> , 2008, 31, 999-1005.	1.5	7
65	Ras-mediated Up-regulation of Survivin Expression in Cytokine-dependent Murine Pro-B Lymphocytic Cells. <i>Tohoku Journal of Experimental Medicine</i> , 2008, 216, 25-34.	0.5	8
66	Bortezomib Overcomes Cell Adhesion-Mediated Drug Resistance Via Down-Regulation of VLA-4 Expression in Multiple Myeloma.. <i>Blood</i> , 2008, 112, 1634-1634.	0.6	2
67	Long-Term Results of Dose-Intensive Chemotherapy With G-CSF Support (TCC-NHL-91) for Advanced Intermediate-Grade Non-Hodgkin's Lymphoma: A Review of 59 Consecutive Cases Treated at a Single Institute. <i>Oncology Research</i> , 2008, 17, 137-149.	0.6	3
68	The expression of rad9 in head and neck cancer. <i>Japanese Journal of Head and Neck Cancer</i> , 2008, 34, 493-497.	0.0	0
69	Rad9 modulates the P21WAF1 pathway by direct association with p53. <i>BMC Molecular Biology</i> , 2007, 8, 37.	3.0	17
70	Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines. <i>Leukemia</i> , 2007, 21, 1005-1014.	3.3	53
71	E2F-6 Suppresses Growth-Associated Apoptosis of Human Hematopoietic Progenitor Cells by Counteracting Proapoptotic Activity of E2F-1. <i>Stem Cells</i> , 2007, 25, 2439-2447.	1.4	25
72	The regulation of Rad9 for therapy of head and neck cancer. <i>Japanese Journal of Head and Neck Cancer</i> , 2007, 33, 425-428.	0.0	0

#	ARTICLE	IF	CITATIONS
73	Histone deacetylase inhibitor FK228 suppresses the Ras/MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma. <i>Oncogene</i> , 2006, 25, 512-524.	2.6	53
74	Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines. <i>Investigational New Drugs</i> , 2006, 25, 31-40.	1.2	46
75	Histone Deacetylase Inhibitor Depsipeptide (FK228) Induces Apoptosis in Leukemic Cells by Facilitating Mitochondrial Translocation of Bax, Which Is Enhanced by the Proteasome Inhibitor Bortezomib. <i>Acta Haematologica</i> , 2006, 115, 78-90.	0.7	48
76	Schedule-Dependent Interactions Between Pemetrexed and Cisplatin in Human Carcinoma Cell Lines In Vitro. <i>Oncology Research</i> , 2006, 16, 85-95.	0.6	16
77	THE ROLE OF RAD9 IN HEAD AND NECK CANCER. <i>Japanese Journal of Head and Neck Cancer</i> , 2006, 32, 417-422.	0.0	1
78	Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228). <i>Journal of Cellular Physiology</i> , 2005, 203, 387-397.	2.0	42
79	Components of DNA Damage Checkpoint Pathway Regulate UV Exposure-Dependent Alterations of Gene Expression of FHIT and WWOX at Chromosome Fragile Sites. <i>Molecular Cancer Research</i> , 2005, 3, 130-138.	1.5	22
80	Methylation Silencing of the Apaf-1 Gene in Acute Leukemia. <i>Molecular Cancer Research</i> , 2005, 3, 325-334.	1.5	78
81	Frag1, a homolog of alternative replication factor C subunits, links replication stress surveillance with apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 9655-9660.	3.3	23
82	Differential Roles of E-Type Cyclins During Transformation of Murine E2F-1-Deficient Cells. <i>DNA and Cell Biology</i> , 2005, 24, 173-179.	0.9	4
83	Pivotal Role of Survivin in Leukemogenesis by E2A-HLF Chimeric Transcription Factor.. <i>Blood</i> , 2005, 106, 2988-2988.	0.6	0
84	Cancer Prevention and Therapy in a Preclinical Mouse Model: Impact of FHIT Viruses. <i>Current Gene Therapy</i> , 2004, 4, 53-63.	0.9	13
85	Differentially expressed genes execute zinc-induced apoptosis in precancerous esophageal epithelium of zinc-deficient rats. <i>Oncogene</i> , 2004, 23, 8040-8048.	2.6	8
86	Alterations of Common Chromosome Fragile Sites in Hematopoietic Malignancies. <i>International Journal of Hematology</i> , 2004, 79, 238-242.	0.7	31
87	Inactivation of ERK accelerates erythroid differentiation of K562 cells induced by herbimycin A and STI571 while activation of MEK1 interferes with it. <i>Molecular and Cellular Biochemistry</i> , 2004, 258, 25-33.	1.4	18
88	Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 505-513.	1.1	14
89	Ectopic cyclin D1 expression blocks STI571-induced erythroid differentiation of K562 cells. <i>Leukemia Research</i> , 2004, 28, 623-629.	0.4	15
90	Effect of exogenous E2F-1 on the expression of common chromosome fragile site genes, FHIT and WWOX. <i>Biochemical and Biophysical Research Communications</i> , 2004, 316, 1088-1093.	1.0	9

#	ARTICLE	IF	CITATIONS
91	Role of cyclins in cAMP inhibition of glomerular mesangial cell proliferation. <i>Clinical Science</i> , 2004, 107, 81-87.	1.8	7
92	Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect. <i>Anticancer Research</i> , 2004, 24, 2705-12.	0.5	24
93	Identification of Novel p53-Binding Proteins by Biomolecular Interaction Analysis Combined with Tandem Mass Spectrometry. <i>Molecular Biotechnology</i> , 2003, 23, 203-212.	1.3	21
94	Alteration of the fragile histidine triad gene early in carcinogenesis: an update. <i>Journal of Experimental Therapeutics and Oncology</i> , 2003, 3, 291-296.	0.5	23
95	Suppression of ARG kinase activity by STI571 induces cell cycle arrest through up-regulation of CDK inhibitor p18/INK4c. <i>Oncogene</i> , 2003, 22, 4074-4082.	2.6	30
96	A novel I-branching \hat{I}^2 -1,6-N-acetylglucosaminyltransferase involved in human blood group I antigen expression. <i>Blood</i> , 2003, 101, 2870-2876.	0.6	77
97	Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. <i>Molecular Cancer Research</i> , 2003, 1, 940-7.	1.5	60
98	Apaf-1 Is a Mediator of E2F-1-induced Apoptosis. <i>Journal of Biological Chemistry</i> , 2002, 277, 39760-39768.	1.6	119
99	Differences in E2F subunit expression in quiescent and proliferating vascular smooth muscle cells. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002, 283, H204-H212.	1.5	7
100	Phosphorylation of Fanconi Anemia Protein, FANCA, Is Regulated by Akt Kinase. <i>Biochemical and Biophysical Research Communications</i> , 2002, 291, 628-634.	1.0	15
101	Cell Cycle Control Genes and Hematopoietic Cell Differentiation. <i>Leukemia and Lymphoma</i> , 2002, 43, 225-231.	0.6	41
102	Hyperglycemia enhances VSMC proliferation with NF- \hat{I}^B activation by angiotensin II and E2F-1 augmentation by growth factors. <i>Molecular and Cellular Endocrinology</i> , 2002, 192, 75-84.	1.6	27
103	Modulation of the erythropoietin-induced proliferative pathway by cAMP in vascular smooth muscle cells. <i>American Journal of Physiology - Cell Physiology</i> , 2002, 283, C1715-C1721.	2.1	19
104	Vasoactive Intestinal Peptide and Cytokines Enhance Stem Cell Factor Production From Epidermal Keratinocytes DJM-1. <i>Journal of Investigative Dermatology</i> , 2002, 119, 1183-1188.	0.3	11
105	Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro. <i>Leukemia</i> , 2002, 16, 1808-1817.	3.3	23
106	Direct Transcriptional Activation of Human Caspase-1 by Tumor Suppressor p53. <i>Journal of Biological Chemistry</i> , 2001, 276, 10585-10588.	1.6	80
107	In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. <i>Blood</i> , 2001, 97, 1999-2007.	0.6	248
108	Vasoactive Intestinal Peptide Regulates its Receptor Expression and Functions of Human Keratinocytes via Type I Vasoactive Intestinal Peptide Receptors. <i>Journal of Investigative Dermatology</i> , 2001, 116, 743-749.	0.3	39

#	ARTICLE	IF	CITATIONS
109	Stimulation of GATA-2 as a mechanism of hydrogen peroxide suppression in hypoxia-induced erythropoietin gene expression. <i>Journal of Cellular Physiology</i> , 2001, 186, 260-267.	2.0	28
110	Schedule-dependent Synergism and Antagonism between Raltitrexed (αTomudex) and Methotrexate in Human Colon Cancer Cell Lines in vitro. <i>Japanese Journal of Cancer Research</i> , 2001, 92, 74-82.	1.7	4
111	Fanconi anemia protein, FANCA, associates with BRG1, a component of the human SWI/SNF complex. <i>Human Molecular Genetics</i> , 2001, 10, 2651-2660.	1.4	81
112	Downregulation of an Aim-1 Kinase Couples with Megakaryocytic Polyploidization of Human Hematopoietic Cells. <i>Journal of Cell Biology</i> , 2001, 152, 275-288.	2.3	58
113	Schedule-Dependent Interaction Between Raltitrexed and 5-Fluorouracil in Human Colon Cancer Cell Lines In Vitro. <i>Oncology Research</i> , 2001, 12, 137-148.	0.6	5
114	Regulation of macrophage-specific gene expression by degenerated lipoproteins. <i>Electrophoresis</i> , 2000, 21, 338-346.	1.3	4
115	Three-dimensional matrix suppresses E2F-controlled gene expression in glomerular mesangial cells. <i>Kidney International</i> , 2000, 57, 1581-1589.	2.6	7
116	Lineage-specific regulation of cell cycle control gene expression during haematopoietic cell differentiation. <i>British Journal of Haematology</i> , 2000, 110, 663-673.	1.2	87
117	In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis. <i>Leukemia</i> , 2000, 14, 379-388.	3.3	30
118	Transcriptional repressor E2F-6 regulates apoptosis of hematopoietic stem cells. <i>Experimental Hematology</i> , 2000, 28, 1504-1505.	0.2	8
119	A Simple Semisolid Subtraction Method Using Carbodiimide-Coated Microplates. <i>Molecular Biotechnology</i> , 2000, 15, 193-200.	1.3	3
120	Tyrosine kinase inhibitors reduce bcl-2 expression and induce apoptosis in androgen-dependent cells. <i>American Journal of Physiology - Cell Physiology</i> , 2000, 278, C66-C72.	2.1	19
121	Induction of Ubiquitin-Conjugating Enzyme by Aggregated Low Density Lipoprotein in Human Macrophages and Its Implications for Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 128-134.	1.1	45
122	Phosphorylation of Bcl-2 Protein by CDC2 Kinase during G2/M Phases and Its Role in Cell Cycle Regulation. <i>Journal of Biological Chemistry</i> , 2000, 275, 21661-21667.	1.6	101
123	Failure of cdc2 promoter activation and G2/M transition by ANG II and AVP in vascular smooth muscle cells. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1999, 277, H515-H523.	1.5	3
124	UDP-GlcNAc:GalNAc-1->3GalNAc (GlcNAc to GalNAc) 1->6N-acetylglucosaminyltransferase holds a key role on the control of CD15s expression in human pre-B lymphoid cell lines. <i>Glycobiology</i> , 1999, 9, 1-12.	1.3	9
125	Transcriptional repression of the E2F-1 gene by interferon-β is mediated through induction of E2F-4/pRB and E2F-4/p130 complexes. <i>Oncogene</i> , 1999, 18, 2003-2014.	2.6	43
126	Interferon-β repressed telomerase along with G1-accumulation of Daudi cells. <i>Cancer Letters</i> , 1999, 142, 23-30.	3.2	21

#	ARTICLE	IF	CITATIONS
127	Defective binding of IRFs to the initiator element of interleukin-1 β -converting enzyme (ICE) promoter in an interferon-resistant Daudi subline. <i>FEBS Letters</i> , 1999, 450, 263-267.	1.3	14
128	Simultaneous core 2 β -N-acetylglucosaminyltransferase up-regulation and sialyl-Le ^x expression during activation of human tonsillar B lymphocytes. <i>FEBS Letters</i> , 1999, 463, 125-128.	1.3	9
129	Single Glycosyltransferase, Core 2 β -N-acetylglucosaminyltransferase, Regulates Cell Surface Sialyl-Le ^x Expression Level in Human Pre-B Lymphocytic Leukemia Cell Line KM3 Treated with Phorbol ester. <i>Journal of Biological Chemistry</i> , 1998, 273, 26779-26789.	1.6	33
130	Human monocyte-endothelial cell interaction induces platelet-derived growth factor expression. <i>Cardiovascular Research</i> , 1998, 37, 216-224.	1.8	41
131	A novel variant of acute myelomonocytic leukemia carrying t(3;12)(q26;p13) with characteristics of 3q21q26 syndrome. <i>International Journal of Hematology</i> , 1998, 67, 361.	0.7	15
132	A Janus Kinase Inhibitor, JAB, Is an Interferon- β -Inducible Gene and Confers Resistance to Interferons. <i>Blood</i> , 1998, 92, 1668-1676.	0.6	52
133	Cell cycle regulation of hematopoietic stem cells. <i>Human Cell</i> , 1998, 11, 81-92.	1.2	33
134	Modulation of E2F Activity Is Linked to Interferon-induced Growth Suppression of Hematopoietic Cells. <i>Journal of Biological Chemistry</i> , 1997, 272, 12406-12414.	1.6	39
135	The Expression of ST2 Gene in Helper T Cells and the Binding of ST2 Protein to Myeloma-Derived RPMI8226 Cells. <i>Journal of Biochemistry</i> , 1997, 121, 95-103.	0.9	94
136	Rapid internalization of exogenous ganglioside GM3 and its metabolism to ceramide in human myelogenous leukemia HL-60 cells compared with control ganglioside GM1. <i>FEBS Letters</i> , 1997, 400, 350-354.	1.3	8
137	Regulatory effects of aggregated LDL on apoptosis during foam cell formation of human peripheral blood monocytes. <i>FEBS Letters</i> , 1997, 409, 177-182.	1.3	16
138	Polyploidization and Functional Maturation Are Two Distinct Processes During Megakaryocytic Differentiation: Involvement of Cyclin-Dependent Kinase Inhibitor p21 in Polyploidization. <i>Blood</i> , 1997, 89, 3980-3990.	0.6	71
139	Cell-Cycle-Dependent Regulation of Erythropoietin Receptor Gene. <i>Blood</i> , 1997, 89, 1182-1188.	0.6	17
140	A LONG-TERMSURVIVAL CASE OF HEPATIC METASTASIS OF RECTAL CARCINOID. <i>The Journal of the Japanese Practical Surgeon Society</i> , 1997, 58, 1079-1083.	0.0	0
141	Cell cycle control during hematopoietic cell differentiation. <i>Human Cell</i> , 1997, 10, 159-64.	1.2	18
142	Interleukin-3-associated ganglioside GD1a is induced independently of normal interleukin-3 receptor in murine myelogenous leukaemia NFS60 cells transfected with the interleukin-3 gene. <i>Glycoconjugate Journal</i> , 1996, 13, 255-261.	1.4	6
143	Transcriptional Activation of the cdc2 Gene Is Associated with Fas-induced Apoptosis of Human Hematopoietic Cells. <i>Journal of Biological Chemistry</i> , 1996, 271, 28469-28477.	1.6	59
144	Herbimycin A down-regulates messages of cyclin D1 and c-myc during erythroid differentiation of K562 cells. <i>International Journal of Hematology</i> , 1996, 65, 31.	0.7	14

#	ARTICLE	IF	CITATIONS
145	Human Monocyte-Endothelial Cell Interaction Induces Synthesis of Granulocyte-Macrophage Colony-Stimulating Factor. <i>Circulation</i> , 1996, 93, 1185-1193.	1.6	61
146	Tenascin-X expression in tumor cells and fibroblasts: glucocorticoids as negative regulators in fibroblasts. <i>Journal of Cell Science</i> , 1996, 109, 2069-2077.	1.2	29
147	Over-expression and amplification of the CDC2 gene in leukaemia cells. <i>British Journal of Haematology</i> , 1995, 90, 94-99.	1.2	8
148	Regulation of EGF-induced tenascin-C by steroids in tenascin-C-non-producing human carcinoma cells. <i>International Journal of Cancer</i> , 1995, 63, 720-725.	2.3	9
149	Apoptosis during HL-60 cell differentiation is closely related to a G0/G1 cell cycle arrest. <i>Journal of Cellular Physiology</i> , 1995, 164, 74-84.	2.0	51
150	Tenascin-C induction by the diffusible factor epidermal growth factor in stromal-epithelial interactions. <i>Journal of Cellular Physiology</i> , 1995, 165, 18-29.	2.0	20
151	Preferential Production of Interleukin-1 ² over Interleukin-1 Receptor Antagonist Contributes to Proliferation and Suppression of Apoptosis in Leukemic Cells. <i>Japanese Journal of Cancer Research</i> , 1995, 86, 208-216.	1.7	19
152	Combination chemotherapy of carboplatin and cytosine arabinoside for high-risk leukemia: A pilot study. <i>Leukemia Research</i> , 1995, 19, 899-903.	0.4	6
153	Expression of Differentiation-Related Phenotypes and Apoptosis Are Independently Regulated during Myeloid Cell Differentiation ¹ . <i>Journal of Biochemistry</i> , 1995, 117, 77-84.	0.9	25
154	Biosynthesis of the So-Called "a" and "Asialo" Pathway Glycosphingolipids Is Differentially Regulated in Murine Myelogenous Leukemia NFS60 Cells. <i>Biochemical and Biophysical Research Communications</i> , 1995, 217, 733-740.	1.0	1
155	Tenascin-C Induction in Whitlock-Witte Culture: A Relevant Role of the Thiol Moiety in Lymphoid-Lineage Differentiation. <i>Experimental Cell Research</i> , 1995, 217, 395-403.	1.2	9
156	The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 1795-1798.	3.3	227
157	Treatment of myeloid leukemic cells with the phosphatase inhibitor okadaic acid induces cell cycle arrest at either G1/S or G2/M depending on dose. <i>Journal of Cellular Physiology</i> , 1992, 150, 484-492.	2.0	94
158	Interleukin 1 production by monocytic leukemia cells and its possible role in coagulation abnormalities. <i>Leukemia Research</i> , 1991, 15, 1133-1137.	0.4	6
159	Heterogeneous expression of the product of the retinoblastoma susceptibility gene in primary human leukemia cells. <i>Oncogene</i> , 1991, 6, 1343-6.	2.6	27
160	Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990, 87, 2770-2774.	3.3	137
161	cdc2 gene expression at the G1 to S transition in human T lymphocytes. <i>Science</i> , 1990, 250, 805-808.	6.0	216
162	Antileukemic effect of nitrous oxide in a patient with chronic myelogenous leukemia. <i>American Journal of Hematology</i> , 1989, 30, 114-114.	2.0	6

#	ARTICLE	IF	CITATIONS
163	The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. <i>Cell</i> , 1989, 58, 1085-1095.	13.5	942
164	Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells. <i>Journal of Immunology</i> , 1989, 143, 3543-7.	0.4	37
165	Cytomegalovirus Gastritis as an Initial Manifestation of a Patient with Adult T-Cell Leukemia. <i>Acta Haematologica</i> , 1988, 80, 216-218.	0.7	16
166	Interleukin-1 derived from human monocytic leukemia cell line JOSK-I acts as an autocrine growth factor. <i>Biochemical and Biophysical Research Communications</i> , 1987, 147, 39-46.	1.0	8
167	Interleukin-1 producing ability of leukaemia cells and its relationship to morphological diagnosis. <i>British Journal of Haematology</i> , 1987, 65, 11-15.	1.2	28
168	Myeloid and erythroid lineage expression of haemopoietic progenitors derived from an abnormal clone in erythroleukaemia. <i>British Journal of Haematology</i> , 1986, 64, 647-656.	1.2	8
169	A case of cytophagic histiocytic panniculitis. <i>Japanese Journal of Clinical Immunology</i> , 1986, 9, 58-64.	0.0	1
170	Establishment and characterization of four human monocytoid leukemia cell lines (JOSK-I, -S, -M and Tj ETQq0 0 0 rgBT /Overlock 10 Tf interleukin 1. <i>Cancer Research</i> , 1986, 46, 3067-74.	0.4	33